Literature DB >> 32857834

Treatment of older patients with atrial fibrillation by morbidity burden.

Peter Vibe Rasmussen1, Jannik Langtved Pallisgaard1, Morten Lock Hansen1, Gunnar Hilmar Gislason1,2,3, Christian Torp-Pedersen4,5,6, Martin Ruwald1, Karen P Alexander7, Renato D Lopes7, Sana M Al-Khatib7, Frederik Dalgaard1,7.   

Abstract

AIMS: Older patients with atrial fibrillation (AF) are at risk of adverse outcomes, which is accentuated by comorbidities. We sought to examine the association between morbidity burden and the treatment of older AF patients. METHODS AND
RESULTS: Using Danish nationwide registers we included patients ≥70 years of age between 2010 and 2017 at their first hospitalization due to AF. Using multiple logistic regression models we examined the association between morbidity burden and the odds of receiving oral anticoagulants (OACs), anti-arrhythmic drugs (AADs), and rhythm-control procedures (direct current cardioversions and catheter ablations). A total of 48 995 patients were included with a majority of women (54%), with a median age of 80 years [interquartile range (IQR) 75-85], and a median morbidity burden of 2 comorbidities (IQR 1-3). Increasing morbidity burden was associated with decreasing odds of OAC treatment with patients having >5 comorbidities having the lowest odds [odds ratio (OR) 0.38, 95% confidence interval (CI) 0.35-0.42] compared to patients with low morbidity burden (0-1 comorbidities). Having >5 comorbidities were associated with increased odds of AAD treatment (OR 1.90, 95% CI 1.64-2.21) and decreased odds of AF procedures (OR 0.39, 95% CI 0.31-0.48), compared to patients with a low morbidity burden (0-1 comorbidities). Examining morbidity burden continuously revealed similar results.
CONCLUSIONS: In older AF patients, multimorbidity was associated with lower odds of receiving OACs and rhythm-control procedures but increased odds of AADs. This presents a clinical conundrum as multimorbid patients potentially benefit the most from treatment with OACs. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Ablation; Aging; Anti-arrhythmic drugs; Atrial fibrillation; Multimorbidity; Oral anticoagulation; Quality of care

Mesh:

Substances:

Year:  2022        PMID: 32857834     DOI: 10.1093/ehjqcco/qcaa070

Source DB:  PubMed          Journal:  Eur Heart J Qual Care Clin Outcomes        ISSN: 2058-1742


  3 in total

1.  Impact of Multimorbidity and Polypharmacy on Clinical Outcomes of Elderly Chinese Patients with Atrial Fibrillation.

Authors:  Agnieszka Kotalczyk; Yutao Guo; Yutang Wang; Gregory Y H Lip
Journal:  J Clin Med       Date:  2022-03-02       Impact factor: 4.241

2.  Multimorbidity and Polypharmacy in Chinese Emergency Department Patients With Atrial Fibrillation and Impacts on Clinical Outcomes.

Authors:  Juan Wang; Yan-Min Yang; Jun Zhu; Han Zhang; Xing-Hui Shao
Journal:  Front Cardiovasc Med       Date:  2022-01-28

3.  Management of Atrial Fibrillation in Older Patients by Morbidity Burden: Insights From Get With The Guidelines-Atrial Fibrillation.

Authors:  Frederik Dalgaard; Haolin Xu; Roland A Matsouaka; Andrea M Russo; Anne B Curtis; Peter Vibe Rasmussen; Martin H Ruwald; Gregg C Fonarow; Angela Lowenstern; Morten L Hansen; Jannik L Pallisgaard; Karen P Alexander; John H Alexander; Renato D Lopes; Christopher B Granger; William R Lewis; Jonathan P Piccini; Sana M Al-Khatib
Journal:  J Am Heart Assoc       Date:  2020-11-26       Impact factor: 5.501

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.